ABT-510 acetate |
Catalog No.GC70733
One-Click Copy Product Info
|
ABT-510 acetate est un peptide TSP anti - angiogénique (analogue de la thrombocytoprotéine - 1) qui induit l'apoptose et inhibe la croissance tumorale ovarienne dans un modèle allogénique in situ de cancer épithélial de l'ovaire.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 442526-87-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ABT-510 acetate (1, 5, 10, 20, 50 nM; 24 h) induces apoptosis in ID8 cells and increases the incidence of apoptosis in the human epithelial cancer cell lines SKOV3, OVCAR3, and CAOV3[1].
ABT-510 acetate (0-10 μM; 7 days) inhibits NO-stimulated vascular cell outgrowth into and invasion through extracellular matrix. ABT-510 acetate blocks tumor-driven vascular cell outgrowth, NO-driven cGMP flux, and CD36-mediated fatty acid uptake. [3].
ABT-510 acetate (100 mg/kg; i.p.; single daily for 90 days) induces cells apoptosis in vivo and leads to a significant reduction in epithelial ovarian tumor size, ascites fluid volume, and secondary lesion dissemination in mice[1].
ABT-510 acetate (60 mg/kg; osmotic minipumps for s.c.; single daily for 7 days) decreases angiogenesis and inflammation in a murine model of inflammatory bowel disease[2].
References:
[1]. Greenaway J, et.al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther. 2009 Jan;8(1):64-74.
[2]. Punekar S,et.al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 2008;75(1):9-21.
[3]. Isenberg JS, et.al. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol. 2008 Feb 15;75(4):875-82.
| Cas No. | 442526-87-6 | SDF | |
| Formula | C48H87N13O13 | M.Wt | 1054.28 |
| Solubility | H2O : 100 mg/mL (94.85 mM; Need ultrasonic) | Storage | Sealed storage, away from moisture and light, under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 948.5 μL | 4.7426 mL | 9.4851 mL |
| 5 mM | 189.7 μL | 948.5 μL | 1.897 mL |
| 10 mM | 94.9 μL | 474.3 μL | 948.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)